Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Cash & Equivalents (2017 - 2025)

Selectis Health's Cash & Equivalents history spans 14 years, with the latest figure at $1.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.0 million for Q4 2025, up 48.7% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 48.7% YoY), and the annual figure for FY2025 was $1.0 million, up 48.7%.
  • Cash & Equivalents for Q4 2025 was $1.0 million at Selectis Health, up from $417125.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $3.1 million in Q3 2023 to a low of $410866.0 in Q1 2021.
  • The 5-year median for Cash & Equivalents is $834955.0 (2022), against an average of $1.0 million.
  • The sharpest move saw Cash & Equivalents crashed 80.95% in 2021, then skyrocketed 269.3% in 2023.
  • Year by year, Cash & Equivalents stood at $853656.0 in 2021, then surged by 183.09% to $2.4 million in 2022, then tumbled by 38.57% to $1.5 million in 2023, then plummeted by 54.17% to $680332.0 in 2024, then soared by 48.7% to $1.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.0 million, $417125.0, and $559983.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.